Ortiz A, Díaz C. Cureus 18(10): e118122. A single, hypothesis-generating case documented by our OrthoBio and Advanced Cellular Therapies teams.
Our newest peer-reviewed publication, from the Auragens OrthoBio Division.
Our Science · Research & Publications
Auragens publishes because the field is full of misconceptions. Our books, research, press coverage and newsletters put what we know into the open, where anyone can read it and judge it.
Auragens’ Journey to #1 on Amazon
One of the pillars of Auragens is transforming the way people understand cellular therapy. We believe it is our obligation to break down the misconceptions and misinformation in the field. Our books take an open, transparent approach: written by our Chief Scientific Officer and our President & CEO, they put the evidence in the hands of anyone who wants to read it.
We empower the individual by educating.
Books
Two of our books have reached the #1 spot on Amazon. Available on Amazon and in person at Auragens.
#1 Amazon Bestseller
#1 Amazon Bestseller


Medical Journals · Advancing Stem Cell Research
Auragens authors and publishes its own research, putting the work behind the treatment where anyone can read it. Below are the studies our team has published, grouped by research focus.
Clinical Case Reports

Ortiz A, Díaz C. Cureus 18(10): e118122. A single, hypothesis-generating case documented by our OrthoBio and Advanced Cellular Therapies teams.
Our newest peer-reviewed publication, from the Auragens OrthoBio Division.

Four patients with chronic lumbar pain were treated with umbilical cord–derived MSCs and exosomes. All four reported reduced pain, with a median reduction of 80.71% on the Visual Analogue Scale, and no adverse reactions were reported. As a small case series without a control group, the findings are preliminary.
This is Auragens’ own treatment protocol, documented patient by patient.
Cellular Aging & Function

Our study found that expression of the NEFH gene declines in human mesenchymal stromal cells as donor age increases.
Donor age is one of the factors we assess when selecting cells, which is why Auracells™ are sourced from umbilical cord tissue.

Analyzing cells from 61 donors aged 17 to 84, we found that KLHL22 expression falls as donor age rises, pointing to gene expression as a way to identify more potent cells for therapy.
The age of the source cells shapes how well they perform, which is why Auracells™ are sourced from umbilical cord tissue.

Our study found a consistent decline in FOSL2 expression with age in bone marrow–derived MSCs, suggesting FOSL2 may be involved in the regulatory networks that influence cellular aging. Further research into its pathways could inform future strategies to support healthspan.
Understanding how cells age informs which cells we select for treatment.
Space & Extreme-Environment Medicine

This study proposes giving astronauts genetically engineered mesenchymal stem cells before Mars missions, as a biological countermeasure against radiation-induced injury. It builds on mouse studies in which modified MSCs improved survival, tissue recovery and blood cell regeneration.
Our research extends beyond the clinic, applying what we know about MSCs to one of the most demanding environments the human body could face.
In the Press
From business awards and scientific presentations to global media features, Auragens is helping shape how the world thinks about recovery, longevity and healing.
As featured in
Newsletters
Our newsletters share our latest research and perspective on cellular therapy, so you can make informed decisions about your health and well-being.




How to Get Started
Start with a candidacy review — no commitment required to find out where you stand.
Contact Us